A1 Refereed original research article in a scientific journal

Follow‐up of osteonecrosis in paediatric acute lymphoblastic leukaemia patients treated with the NOPHO ALL2008 protocol




AuthorsRokkanen, Roosa; Aarnivala, Henri; Huhtaniska, Sanna; Palmu, Sauli; Pokka, Tytti; Pöyhönen, Tuuli; Suo‐Palosaari, Maria; Utriainen, Pauliina; Järvelä, Liisa; Niinimäki, Riitta

PublisherWiley

Publication year2025

JournalBritish Journal of Haematology

Journal name in sourceBritish Journal of Haematology

Article numberbjh.70085

ISSN0007-1048

eISSN1365-2141

DOIhttps://doi.org/10.1111/bjh.70085

Web address https://doi.org/10.1111/bjh.70085

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/499693400


Abstract

Although osteonecrosis (ON) is a common sequel after childhood acute lymphoblastic leukaemia treatment and may cause debilitating symptoms, its prognosis remains underexplored. We describe the radiological evolution of ON lesions in a Finnish patient cohort treated according to the The Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL2008 protocol. We aimed to identify the factors influencing the outcome of ON. We collected data from 37 patients diagnosed with ON treated in five tertiary centres. We analysed magnetic resonance imaging scans containing 235 ON lesions (109 affecting joints) and graded them using the Niinimäki classification system. The mean follow-up time from an ON diagnosis was 3.3 years (SD 3.4 range: 0.04–13.5). Among the lesions with follow-up scans, 55% remained stable, 35% resolved, 8% improved to lower grade and 2% progressed. Joint collapse was observed in 18 joint lesions (17%). Factors associated with unfavourable outcomes were female sex, older age at diagnosis and haematopoietic stem cell transplantation (HSCT). The chance for spontaneous resolution of ON was lower in females (adjusted odds ratio [aOR] 10.3, 95% CI 2.0–52.6) and decreased with age (aOR 1.4, 95% CI 1.1–1.7), whereas HSCT was associated with joint collapse already at ON diagnosis (aOR 8.3, 95% CI 2.6–27.0).


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.




Funding information in the publication
This work was supported by a grant from the Paediatric Cancer Foundation Aamu and the Snellman Foundation (grants to Roosa Rokkanen). Additionally, Riitta Niinimäki received funding for university-level health research at Oulu University Hospital, the Wellbeing Services County of North Ostrobothnia and Finnish State Research Funding granted by the Ministry of Social Affairs and Health and from the Väre Foundation for Paediatric Cancer Research. Open access publishing facilitated by Oulun yliopisto, as part of the Wiley - FinELib agreement.


Last updated on 2025-15-09 at 12:26